SOLID BIOSCIENCES INC (SLDB)
US83422E2046 - Common Stock
SLDB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. SLDB has a bad profitability rating. Also its financial health evaluation is rather negative. SLDB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SLDB had negative earnings in the past year.
In the past year SLDB has reported a negative cash flow from operations.
In the past 5 years SLDB always reported negative net income.
In the past 5 years SLDB always reported negative operating cash flow.
1.2 Ratios
SLDB has a Return On Assets (-58.21%) which is in line with its industry peers.
SLDB has a Return On Equity (-75.91%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.21% | ||
| ROE | -75.91% | ||
| ROIC | N/A |
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SLDB does not have a ROIC to compare to the WACC, probably because it is not profitable.
SLDB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SLDB has been increased compared to 5 years ago.
Compared to 1 year ago, SLDB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.33, we must say that SLDB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.33, SLDB is not doing good in the industry: 60.54% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.01 indicates that SLDB is not too dependend on debt financing.
The Debt to Equity ratio of SLDB (0.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.33 |
ROIC/WACCN/A
WACC10.69%
2.3 Liquidity
A Current Ratio of 8.94 indicates that SLDB has no problem at all paying its short term obligations.
The Current ratio of SLDB (8.94) is better than 76.94% of its industry peers.
SLDB has a Quick Ratio of 8.94. This indicates that SLDB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.94, SLDB is in the better half of the industry, outperforming 77.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 54.08% over the past year.
SLDB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)54.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SLDB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.01% yearly.
Based on estimates for the next years, SLDB will show a very strong growth in Revenue. The Revenue will grow by 167.00% on average per year.
EPS Next Y37.45%
EPS Next 2Y17.63%
EPS Next 3Y10.98%
EPS Next 5Y12.01%
Revenue Next Year-100%
Revenue Next 2Y-44.33%
Revenue Next 3Y-25.99%
Revenue Next 5Y167.01%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SLDB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.63%
EPS Next 3Y10.98%
5. Dividend
5.1 Amount
SLDB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOLID BIOSCIENCES INC
NASDAQ:SLDB (1/8/2025, 8:00:01 PM)
After market: 4.01 -0.02 (-0.5%)4.03
+0.11 (+2.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners79.89%
Inst Owner Change0%
Ins Owners0.85%
Ins Owner Change0.24%
Market Cap161.00M
Analysts85.88
Price Target17.34 (330.27%)
Short Float %5.38%
Short Ratio5.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.06%
Min EPS beat(2)0.77%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)15.66%
Min EPS beat(4)0.77%
Max EPS beat(4)28.35%
EPS beat(8)5
Avg EPS beat(8)-3.01%
EPS beat(12)9
Avg EPS beat(12)5.93%
EPS beat(16)12
Avg EPS beat(16)5.24%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.46%
PT rev (3m)-8.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.33%
EPS NY rev (3m)-12.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.27 | ||
| P/tB | 1.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.04
EYN/A
EPS(NY)-2.96
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.36
OCFYN/A
SpS0
BVpS3.17
TBVpS3.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.21% | ||
| ROE | -75.91% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.7% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.94 | ||
| Quick Ratio | 8.94 | ||
| Altman-Z | -4.33 |
F-Score1
WACC10.69%
ROIC/WACCN/A
Cap/Depr(3y)75.75%
Cap/Depr(5y)81.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.76%
EPS Next Y37.45%
EPS Next 2Y17.63%
EPS Next 3Y10.98%
EPS Next 5Y12.01%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-44.33%
Revenue Next 3Y-25.99%
Revenue Next 5Y167.01%
EBIT growth 1Y-5.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.93%
EBIT Next 3Y-11.03%
EBIT Next 5YN/A
FCF growth 1Y5.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.88%
OCF growth 3YN/A
OCF growth 5YN/A